



SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND ANTIMETABOLITE COMPOUNDS

The present invention relates in general to the field of cancer treatment and, more particularly, provides an antitumor composition comprising an alkylating anthracycline and an antimetabolite compound, having a synergistic or additive antineoplastic effect.

The present invention provides, in a first aspect, a pharmaceutical composition for use in antineoplastic therapy in mammals, including humans, comprising

- 10 - an alkylating anthracycline of formula Ia or Ib :



- an antimetabolite compound, and a pharmaceutically acceptable carrier or excipient.

- 15 The chemical names of the alkylating anthracyclines of formula Ia and Ib are 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin (Ia) and 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin (Ib). These alkylating anthracyclines were described in Anticancer Drug Design (1995), vol. 10, 641-653, and claimed respectively in US-A-5,532,218 and US-A-5,496,800. Both compounds intercalate into DNA via the chromophore and alkylate guanine at N<sup>7</sup> position in DNA major groove via their reactive moiety on position 3' of the amino sugar. Compounds Ia and Ib are able to circumvent the resistance to all major classes of
- 25

cytotoxics, indicating that the compounds represent a new class of cytotoxic antitumor drugs.

Antimetabolites are described in various scientific

publications. The main representatives of this wide class of

5 drugs are: the antifolates such as methotrexate, raltitrexed and trimetrexate; the 5-fluoropyrimidine compounds such as 5-fluorouracil, floxuridine and capecitabine; the cytidine analogs like cytarabine, azacitidine and gemcitabine. See for example the review: Cancer, Principles and Practice of

10 Oncology, Lippincott-Raven Ed. (1997), 432-452. The 5-fluoropyrimidine compounds and the cytidine analogs are the preferred antimetabolite compounds to be used in the present invention, more preferably 5-fluorouracil or gemcitabine. The present invention also provides a product comprising an  
15 alkylating anthracycline of formula Ia or Ib as defined above and an antimetabolite compound, as combined preparation for simultaneous, separate or sequential use in antitumor therapy.

A further aspect of the present invention is to provide a  
20 method of treating a mammal including humans, suffering from a neoplastic disease state comprising administering to said mammal an alkylating anthracycline of formula Ia or Ib as defined above and an antimetabolite compound, in amounts effective to produce a synergistic antineoplastic effect.

25 The present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in mammals, including humans, in need thereof, the method comprising administering to said mammal a combination preparation comprising an antimetabolite compound  
30 as defined above and an alkylating anthracycline of formula Ia or Ib, as defined above, in amounts effective to produce a synergistic antineoplastic effect.

By the term "a synergistic antineoplastic effect" as used herein is meant the inhibition of the growth tumor,

10031371.043000

preferably the complete regression of the tumor,  
administering an effective amount of the combination of an  
alkylating anthracycline of formula Ia or Ib as defined above  
and a antimetabolite compound to mammals, including human.

- 5 By the term "administered " or "administering" as used herein  
is meant parenteral and /or oral administration. By  
"parenteral" is meant intravenous, subcutaneous and  
intramuscular administration. In the method of the subject  
invention, the alkylating anthracycline may be administered  
10 simultaneously with the compound with the antimetabolite  
compound activity, for example of the 5-fluoropyrimidine or  
cytidine class, or the compounds may be administered  
sequentially, in either order. It will be appreciated that  
the actual preferred method and order of administration will  
15 vary according to, inter alia, the particular formulation of  
the alkylating anthracycline of formula Ia or Ib being  
utilized, the particular formulation of the antimetabolite  
compound, such as one of the 5-fluoropyrimidine or cytidine  
class, being utilized, the particular tumor model being  
20 treated, and the particular host being treated.  
In the method of the subject invention, for the  
administration of the alkylating anthracycline of formula Ia  
or Ib, the course of therapy generally employed is from about  
0.1 to about 200 mg/m<sup>2</sup> of body surface area. More preferably,  
25 the course therapy employed is from about 1 to about 50 mg/m<sup>2</sup>  
of body surface area.  
In the method of the subject invention, for the  
administration of the antimetabolite compound the course of  
therapy generally employed is from about 0.1 to about 10 g/m<sup>2</sup>  
30 of body surface area. More preferably, the course therapy  
employed is from about 1 mg/m<sup>2</sup> to about 5 g/m<sup>2</sup> of body surface  
area. The antineoplastic therapy of the present invention is  
in particular suitable for treating breast, ovary lung,

colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans.

In a further aspect, the present invention is directed to the preparation of a pharmaceutical composition containing an effective amount of an alkylating anthracycline of formula Ia or Ib as defined above and an antimetabolite compound in the prevention or treatment of metastasis or for the treatment of tumors by angiogenesis inhibition, as well as to the use of an alkylating anthracycline of formula Ia or Ib as defined above and an antimetabolite compound for the treatment of tumors by angiogenesis inhibition or for the treatment or prevention of metastasis.

As stated above, the effect of an alkylating anthracycline of formula Ia or Ib and an antimetabolite compound, such as a 5-fluoropyrimidine or cytidine derivative, is significantly increased without a parallel increased toxicity. In other words, the combined therapy of the present invention enhances the antitumoral effects of the alkylating anthracycline and of the antimetabolites and thus yields the most effective and least toxic treatment for tumors.

The superadditive actions of the combination preparation of the present invention may be shown for instance by in vivo tests for the antileukemic activity on disseminated L1210 murine leukemia. The combination of Ia with gemcitabine (Table 1) or 5-Fluorouracil tested at the different doses and schedules, produces favorable ILS% values (Increase in life span:  $[(\text{median survival time of treated mice} / \text{median survival time of controls}) \times 100] - 100$ ), indicating a synergistic effect.

Table 1 shows the antileukemic activity on disseminated L1210 murine leukemia obtained by combining the above PNU 159548 derivative with gemcitabine.

At the dose of 15 and 60 mg/kg of gemcitabine alone (ip day 1 after tumor injection) and at the dose of 1 and 1.5 mg/kg of PNU 159548 alone (iv day 1 after tumor injection, administered 2h after gemcitabine) were associated, without toxicity, with ILS% values of 50 and 83 and 33 and 67, respectively. By combining gemcitabine and PNU 159548 at the same doses and with the same schedule, an increase of activity with ILS% values of 117 and 204 were observed, indicating a synergistic effect as shown by the combination index (CI) of 1.4 and 1.3, respectively.

**Table 1:** Antileukemic activity against disseminated L1210<sup>1</sup> murine leukemia of PNU-159548 (I) in combination with gemcitabine

Compound	Treatment schedule	Dose (mg/kg/day)	ILS% <sup>2</sup>	LTS <sup>3</sup>	TOX <sup>4</sup>	CI <sup>5</sup>
PNU 159548	iv +1(*)	1	33	0/10	0/10	NA
		1.5	67	0/20	0/20	NA
Gemcitabine	ip +1	15	50	0/10	0/10	NA
		60	83	0/20	0/20	NA
PNU 159548 + gemcitabine	iv +1(*) ip +1	1 + 15	117	0/10	0/10	1.4
		1.5 + 60	204	4/20	2/20	1.3

1. L1210 leukemia cells ( $10^5$ /mouse CD2F1) are injected IV on Day 0.
2. Increase in life span: [(median survival time of treated mice/median survival time of controls) x 100] -100.
3. LTS: long-term survivors (>60 days) at the end of the experiments
4. Number of toxic deaths/number of mice.
5. C.I. = combination Index : <1 antagonistic; 1 additive; >1 synergistic  
(\*)administered 2h after gemcitabine  
NA: not applicable

For these experiments Ia was solubilized in [Cremophor® /EtOH = 6.5:3.5]/[normal saline]=20/80 v/v, while standard pharmaceutical preparation were used for the antimetabolite compounds.